Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.3942
+0.0292 (8.00%)
At close: Jun 11, 2026, 4:00 PM EDT
0.3867
-0.0075 (-1.90%)
After-hours: Jun 11, 2026, 7:56 PM EDT
Werewolf Therapeutics Employees
Werewolf Therapeutics had 39 employees as of December 31, 2025. The number of employees decreased by 7 or -15.22% compared to the previous year.
Employees
39
Change
-7
Growth
-15.22%
Revenue / Employee
n/a
Profits / Employee
-$1,442,692
Market Cap
19.16M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 39 | -7 | -15.22% |
| Sep 30, 2025 | 39 | -6 | -13.33% |
| Jun 30, 2025 | 46 | 1 | 2.22% |
| Mar 31, 2025 | 46 | 0 | - |
| Dec 31, 2024 | 46 | -1 | -2.13% |
| Sep 30, 2024 | 45 | -1 | -2.17% |
| Jun 30, 2024 | 45 | -3 | -6.25% |
| Mar 31, 2024 | 46 | 0 | - |
| Dec 31, 2023 | 47 | 1 | 2.17% |
| Sep 30, 2023 | 46 | -2 | -4.17% |
| Jun 30, 2023 | 48 | 1 | 2.13% |
| Mar 31, 2023 | 46 | 4 | 9.52% |
| Dec 31, 2022 | 46 | 7 | 17.95% |
| Sep 30, 2022 | 48 | 12 | 33.33% |
| Jun 30, 2022 | 47 | 16 | 51.61% |
| Mar 31, 2022 | 42 | 14 | 50.00% |
| Dec 31, 2021 | 39 | 15 | 62.50% |
| Sep 30, 2021 | 36 | 12 | 50.00% |
| Jun 30, 2021 | 31 | - | - |
| Mar 31, 2021 | 28 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Passage Bio | 24 |
| Curis | 24 |
| Lipocine | 14 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| AEON Biopharma | 8 |
| Traws Pharma | 7 |
HOWL News
- 5 weeks ago - Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 5 weeks ago - Werewolf Therapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Werewolf Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Werewolf Therapeutics hires Piper Sandler to assist in strategic evaluation - TheFly
- 2 months ago - Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c) - TheFly
- 2 months ago - Werewolf Therapeutics to explore range of strategic alternatives - TheFly
- 2 months ago - Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Annual report: Q4 2025 - Filings